STAR*D: A tale and trail of bias

Ethical Human Psychology and Psychiatry

Volumn 13, Issue 1, 2011, Pages 6-28

  Pigott, H Edmund ^a  

^a Paraclete Professionals   (United States)

Author keywords

Antidepressants; Major depression; Researcher bias; STAR*D

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; EFFEXO; LIOTHYRONINE; LIOTHYRONINE SODIUM; LITHIUM; MIRTAZAPINE; NORTRIPTYLINE; SERTRALINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); COMORBIDITY; DEPRESSION; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; METHODOLOGY; MORBIDITY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEQUENCED TREATMENT ALTERNATIVES TO RELIEVE DEPRESSION STUDY; SYMPTOM;

EID: 79953737166     PISSN: 15594343     EISSN: 19389000     Source Type: Journal    
DOI: 10.1891/1559-4343.13.1.6     Document Type: Article

References (66)

1. Affordable Care Act. (2010). Preventive services covered under the Affordable Care Act. Retrieved November 12, 2010, from http://www.healthcare.gov/law/about/provisions/services/lists.html
2. American Psychiatric Association. (2000). Practice guideline for the treatment of patients with major depressive disorder (2nd ed.). Washington, DC: Author.
3. Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2009). Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. The American Journal of Psychiatry, 166(5), 591-598.
4. Barbui, C., Furukawa, T. A., & Cipriani, A. (2008). Effectiveness of paroxetine in the treatment of acute major depression in adults: A systematic re-examination of published and unpublished data from randomized trials. Canada Medical Association Journal, 178(3), 296-305.
5. Bockting, C. L. H., ten Doesschate, M. C., Spijker, J., Spinhoven, P., Koeter, M. W., & Schene, A. H. (2008). Continuation and maintenance use of antidepressants in recurrent depression. Psychotherapy and Psychosomatics, 77(1), 17-26.
6. Boren, J. (2007). The effectiveness of antidepressant medications: Results from a major new study. The Behavior Therapist, 30, 96-98.
7. Chan, A. W., Krleza-Jerić, K., Schmid, I., & Altman, D. G. (2004). Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Canadian Medical Association Journal, 171(7), 735-740.
8. Davidson, J. R. T., Gadde, K. M., Fairbank, J. A., Krishnan, R. R., Califf, R. M., & Binanay, C., et al. (2002). Effect of Hypericum perforatum (St John's Wort) in major depressive disorder: A randomized controlled trial. The Journal of the American Medical Association, 287(14), 1807-1814.
9. Eyding, D., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., et al. (2010). Reboxetine for acute treatment of major depression: Systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. British Medical Journal, 341, c4737. doi:10.1136/bmj.c4737.
10. Fava, G. A. (1994). Do antidepressant and antianxiety drugs increase chronicity in affective disorders? Psychotherapy and Psychosomatics, 61(3-4), 125-131.
11. Fava, G. A. (2003). Can long-term treatment with antidepressant drugs worsen the course of depression? The Journal of Clinical Psychiatry, 64(2), 123-133.
12. Fava, G. A., & Offidani, E. (2010). The mechanisms of tolerance in antidepressant action. Progress in Neuro-Psychopharmacology & Biological Psychiatry. Prepublication accessed online at doi:10.1016/j.pnpbp.2010.07.026
13. Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003). The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach. Psychotherapy and Psychosomatics, 72(3), 115-127.
14. Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., et al. (2003). Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatric Clinics of North America, 26(2), 457-494.
15. Fava, M., Rush, A. J., Wisniewski, S. R., Nierenber, A. A., Alpert, J. E., McGrath, P. J., et al. (2006). A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. American Journal of Psychiatry, 163, 1161-1172.
16. Gaynes, B. N., Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Spencer, D., & Fava, M. (2008). The STAR*D study: Treating depression in the real world. Cleveland Clinic Journal of Medicine, 75(1), 57-66.
17. Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet, 361(9358), 653-661.
18. Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Beglund, P. A., et al. (2003). The economic burden of depression in the United States: How did it change between 1990 and 2000? The Journal of Clinical Psychiatry, 64(12), 1465-1475.
19. Insel, T. R. (2009). Disruptive insights in psychiatry: Transforming a clinical discipline. Journal of Clinical Investigation, 119(4), 700-705.
20. Kerr, N. L. (1998). HARKing: hypothesizing after the results are known. Personality and Social Psychology Review, 2(3), 196-217.
21. Kessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P. A., Hirschfeld, R. M., et al. (2006). Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. The American Journal of Psychiatry, 163(9), 1561-1568.
22. Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 62(6), 617-627.
23. Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45.
24. Kirsch, I., Moore, T. J., Scoboria, A., & Nicholls, S. S. (2002). The emperor's new drugs: An analysis of antidepressant medication data submitted to the U. S. Food and Drug Administration. Prevention & Treatment, 5, Article 23.
25. Mathieu, S., Boutron, I., Moher, D., Altman, D. G., & Ravaud, P. (2009). Comparison of registered and published primary outcomes in randomized controlled trials. The Journal of the American Medical Association, 302(9), 977-984.
26. Mojtabai, R., & Olfson, M. (2008). National patterns in antidepressant treatment by psychiatrists and general medical providers: Results from the national comorbidity survey replication. Journal of Clinical Psychiatry, 69(7), 1064-1074.
27. Mojtabai, R., & Olfson, M. (2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry, 67(1), 26-36.
28. National Committee for Quality Assurance. (2009). Antidepressant medication management (effective continuation phase treatment): Percentage of members who were diagnosed with a new episode of major depression, treated with antidepressant medication, and who remained on an antidepressant medication for at least 180 days (6 months). Retrieved November 12, 2010, from http://www .qualitymeasures.ahrq.gov/content.aspx?id=14961
29. National Institute of Mental Health. (2002). Sequenced Treatment Alternatives to Relieve Depression (STAR*D) contract protocol (Rev. ed.). Retrieved October 1, 2010, from Freedom of Information Act.
30. National Institute of Mental Health. (2006a). New strategies help depressed patients become symptomfree. Retrieved July 5, 2010, from http://www.nimh.nih.gov/science-news/2006/new-strategieshelp-depressed-patients-become-symptom-free.shtml
31. National Institute of Mental Health. (2006b). Odds of beating depression diminish as additional treatment strategies are needed. Retrieved July 5, 2010, from http://www.nimh.nih.gov/science-news/2006/odds-of-beating-depression-diminish-as-additional-treatment-strategies-are-needed.shtml
32. National Institute of Mental Health. (2006c). Questions and answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study-All medication levels. Retrieved July 5, 2010, from http://www.nimh.nih.gov/trials/practical/stard/allmedicationlevels.shtml
33. National Institute of Mental Health. (2006d). Switching to a third antidepressant medication may prove helpful to some with treatment-resistant depression. Retrieved July 5, 2010, from http://www.nimh .nih.gov/science-news/2006/switching-to-a-third-antidepressant-medication-may-prove-helpfulto-some-with-treatment-resistant-depression.shtml
34. National Institute of Mental Health. (2009). Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Retrieved July 5, 2010, from http://www.clinicaltrials.gov/ct/show/NCT00021528?order=1
35. National Institute of Mental Health. (2010a, September 29). [Letter in response to FOIA] case # 37933.
36. National Institute of Mental Health. (2010b). Available limited access datasets from NIMH clinical trials; Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Retrieved December 3, 2010, from http://www.nimh.nih.gov/trials/datasets/nimh-procedures-for-requesting-data-sets.shtml
37. National Institute of Mental Health STAR*D Contract # N01MH90003. (1999, September 29). Obtained through the Freedom of Information Act, October 1, 2010.
38. Nelson, J. C., & Papakostas, G. I. (2009). Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. The American Journal of Psychiatry, 166(9), 980-991.
39. Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski S. R., et al. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR*D report. Psychological Medicine, 40(1), 41-50.
40. Olfson, M., & Marcus, S. C. (2009). National patterns in antidepressant medication treatment. Archives of General Psychiatry, 66(8), 848-856.
41. O'Neal, B., & Biggs, M. (2001). STAR*D patient education manual. Retrieved July 5, 2010, from http://www.edc.pitt.edu/stard/public/study_manuals.html
42. Perlis, R. H., Purcell, S., Fava, M., Fagerness, J., Rush, A. J., Trivedi, M. H., et al. (2007). Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Archives of General Psychiatry, 64(6), 689-697.
43. Pigott, H. E. (2010a, August 17). [FOIA letter requesting STAR*D's Contract Protocol, Statistical Analytic Plan, minutes from Data Safety and Monitoring Board meetings, and the quarterly and annual reports filed by the investigators as part of contract] N01 MH-90003.
44. Pigott, H. E. (2010b, October 14). [FOIA letter requesting all data analytic reports provided by STAR*D's investigators to NIMH as part of contract] N01 MH-90003.
45. Pigott, H. E. (2010c, December 3). Notes from December 3rd 2010 conference call with George Niederehe, government program officer responsible for STAR*D, Stephen Wisniewski, STAR*D chief biostatistician, and Lisa Alberts, NIMH Freedom of Information coordinator.
46. Pigott, H. E. (2011d, January 12). FOIA letter requesting for contract N01 MH-90003 the contractually mandated (pages 19-20): (1) quarterly reports to the Data Safety and Monitoring Board; (2) the annual reports; and (3) the Study Final Report including all " statistical analyses performed in text, tabular, and graphical form."
47. Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J. (2010). Efficacy and effectiveness of antidepressants: Current status of research. Psychotherapy and Psychosomatics, 79(5), 267-279.
48. Rising, K., Bacchetti, P., & Bero, L. (2008). Reporting bias in drug trials submitted to the Food and Drug Administration: A review of publication and presentation. PLoS Medicine, 5(11), e217.
49. Rush, A. J., Bernstein, I. H., Trivedi, M. H., Carmody, T. J., Wisniewski, S. R., Mundt, J. C., et al. (2006). An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A sequenced treatment alternatives to relieve depression trial report. Biological Psychiatry, 59(6), 493-501.
50. Rush, A. J, Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., et al. (2004). Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Controlled Clinical Trials, 25(1), 119-142.
51. Rush, A. J., Trivedi, M. H., Carmody, T. J., Biggs, M. M., Shores-Wilson, K., Ibrahim, H., et al. (2004). One-year clinical outcomes of depressed public sector outpatients: A benchmark for subsequent studies. Biological Psychiatry, 56(1), 46-53.
52. Rush A. J., Trivedi, M. H., Wisniewski S. R., Nierenberg A. A., Stewart J. W., Warden D., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. The American Journal of Psychiatry, 163(11), 1905-1917.
53. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase M., et al. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. The New England Journal of Medicine, 354(12), 1231-1242.
54. ScienceDaily. (2008a, June 16). Groundbreaking depression research being tested in real-world setting. Retrieved November 13, 2010, from http://www.sciencedaily.com/releases/2008/06/080612070402.htm
55. ScienceDaily. (2008b, July 22). Testing multiple medication treatment of depression. Retrieved November 13, 2010, from http://www.sciencedaily.com/releases/2008/07/080722072021.htm
56. Sunderajan, P., Gaynes, B. N., Wisniewski, S. R., Miyahara, S., Fava, M., Akingbala, F., et al. (2010). Insomnia in patients with depression: A STAR*D report. CNS Spectrums, 15(6), 394-404.
57. Thase, M. E. (2007). Two new sections offer further checks and balances: Negative and failed clinical trial reports and invited commentary. Psychopharmacology Bulletin, 40, 5.
58. Trivedi, M. H., Fava, M., Wisniewski, S., Thase, M. E., Quitkin, F., Warden, D., et al. (2006). Medication augmentation after the failure of SSRIs for depression. The New England Journal of Medicine, 354, 1243-1252.
59. Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. The American Journal of Psychiatry, 163(1), 28-40.
60. Trivedi, M. H., Stegman, D., Rush, A. J., Wisniewski, S. R., & Nierenberg, A. A. (2002). STAR*D clinical procedures manual. Retrieved August 1, 2010, from http://www.edc.pitt.edu/stard/public/study_manuals.html
61. Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. The New England Journal of Medicine, 358(3), 252-260.
62. Vedula, S. S., Bero, L., Scherer, R. W., & Dickersin, K. (2009). Outcome reporting in industrysponsored trials of gabapentin for off-label use. The New England Journal of Medicine, 361(20), 1963-1971.
63. Whitaker, R. (2005). Anatomy of an epidemic: Psychiatric drugs and the astonishing rise of mental illness in America. Ethical Human Psychology and Psychiatry, 7(1), 23-35.
64. Whitaker, R. (2010). Anatomy of an epidemic: Magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America. New York: Crown Publishers.
65. Yury, C. A., Fisher, J. E., Antonuccio, D. O., Valenstein, M., & Matuszak, J. (2009). Meta-analysis of antidepressant augmentation: Piling on in the absence of evidence. Ethical Human Psychology and Psychiatry, 11(3), 171-182.
66. Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? The American Journal of Psychiatry, 159(3), 469-473.